The price has already run
Elbit Systems stock trades near $783 a share today, up from roughly $200 in early 2024. The promo that brought it to investors’ attention, Dylan Jovine’s “The Arsenal,” leans on a “up 121% since our recommendation” claim, and that number is measured from Jovine’s own entry point, not from anything a new buyer can capture today. A stock that has roughly quadrupled in two years is a different purchase than the one the analyst made near $200.
The company behind the ticker is real, and the fundamentals have improved along with the price. Our Elbit Systems Ltd profile walks through what the business actually does, from Iron Dome and David’s Sling supplier work to the land-based artillery and munitions that drive today’s earnings.
The valuation math, laid out
Elbit’s order backlog has swollen past $30 billion for the first time in its history, a figure StockGumshoe confirmed. Against a market cap north of $35 billion, that means the entire current equity value is roughly matched by contracted work. That is a strong base of visibility, and it is the single most reassuring number in the pitch.
The problem is the multiple. At roughly $783 a share, the stock trades near 44 times next-year earnings of about $18, with revenue growth expected around 10% beyond 2026. Paying 44 times for 10% growth is a high price in any sector, and it is a high price for a defense contractor specifically, because these businesses tend to compound steadily rather than sprint. The earnings estimate itself has moved up sharply, from about $7 a share by 2026 back in early 2024 to near $17 today, but the stock has outrun even that improvement.
Track record versus today’s entry
The distinction that matters here is between a call and a price. Jovine first pitched Elbit early in 2024 as “Israel’s Brand New Weapon,” emphasizing the laser-weapons angle, and the call has clearly worked. We cover how that call evolved and where it stands in our Dylan Jovine profile piece. But a track record is a statement about the past. Today’s buyer is making a statement about the future at a much higher valuation.
The demand picture is still favorable. NATO members are moving toward the 2% of GDP defense-spending guideline, several European governments are already beyond it, and Western stockpiles remain depleted after three years of drawdowns. Combat-proven systems carry a real procurement edge. None of that has changed. What has changed is how much of that future is already priced in.
What a new buyer is really signing up for
Buying Elbit near $783 means accepting that the next leg of the rearmament decade, not the first one, will justify the price. The backlog supports steady revenue for years, and the diversified customer base, with Israel accounting for just over a quarter of revenue and NATO and allied buyers for the rest, reduces single-country risk. Those are real strengths.
The honest framing is that this is a quality business at a demanding price, not a hidden gem at a bargain. The promo’s 121% figure belongs to the analyst’s earlier entry. A reader deciding today should measure the stock against today’s price and today’s multiple, which is the same discipline we applied to the earlier promo in our Arsenal teardown.
What the multiple is asking you to believe
At roughly 44 times next-year earnings, the market is pricing Elbit as if the current growth rate and the backlog conversion will persist for years without a stumble. That is a demanding assumption for any defense contractor, because these businesses are tied to government budget cycles and contract timing, both of which can slip. A delayed order or a budget reprioritization does not change the long-term story, but it can move a stock that carries a 44-times multiple much harder than one at a cheaper valuation.
The earnings estimates themselves tell a clear story of improvement. Early in 2024, analysts expected about $7 a share by 2026. The consensus now sits near $17 for 2026 and about $18 the following year, with roughly 10% revenue growth after that. That is a sharp upgrade, and it justifies a higher price than the stock carried two years ago. The question is whether it justifies this price, roughly four times the early-2024 level.
A buyer today is paying for a decade of rearmament that is already partially reflected in the share price. The backlog is real, the demand is real, and the customer base is diversified. The multiple is the risk. Quality is not the same as value, and a company can be excellent and still be fully priced.
Ready to see the research? Click here to access Dylan Jovine’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.